Rothamsted Research Granted Permission by Defra for Trials with GM Plants
Scientists at Rothamsted Research, in collaboration with researchers at the University of Essex and Lancaster University, have developed wheat plants that can carry out photosynthesis more efficiently i.e. convert light energy into plant biomass more efficiently. This trait has the potential to result in higher yielding plants. The purpose of the proposed trial is to evaluate the performance of the engineered plants in the field.
Ensuring food security is a major challenge given the projected need to increase world food production by 40% in the next 20 years and 70% by 2050. Wheat is one of the major grain crops worldwide and provides approximately one-fifth of the total calories consumed globally. However, wheat yields have reached a plateau in recent years and predictions are that yield gains will not reach the level required to feed the 9 billion population predicted for 2050. Traditional breeding and agronomic approaches have maximised light capture and allocation to the grain. A promising but as yet-unexploited route to increase wheat yields is to improve the efficiency by which energy in the form of light is converted to wheat biomass.
Professor Christine Raines, Head of the School of Biological Sciences at the University of Essex and principal investigator for this research project, said: “The efficiency of the process of photosynthesis integrated over the season is the major determinant of crop yield. However, to date photosynthesis has not been used to select for high yielding crops in conventional breeding programmes and represents an unexploited opportunity. But there is now evidence that improving the efficiency of photosynthesis by genetic modification is one of the promising approaches to achieve higher wheat yield potential.”
“In this project we have genetically modified wheat plants to increase the efficiency of the conversion of energy from sunlight into biomass. We have shown that these plants carry out photosynthesis more efficiently in glasshouse conditions. One of the steps in photosynthesis shown to limit this process is carried out by the enzymesedoheptulose-1,7-biphosphatase (SBPase). We have engineered GM wheat plants to produce increased levels of SBPase by introducing an SPBase gene from Brachypodium distachyon (common name stiff brome), a plant species related to wheat and used as a model in laboratory experiments” Christine added.
Dr Elizabete Carmo-Silva, co-investigator in this project at Lancaster University, added: “We have produced two types of plants, one in which two extra copies of SBPase are functional and one in which six extra copies of SBPase are functional. During the field trial, we will measure the photosynthetic efficiency of the plants in the field and we will determine total aboveground plant biomass and grain yield on an area basis at full maturity. We will also measure the number of wheat ears on an area basis and the grain number and weight per ear. From these data we will estimate the harvest index, which is the proportion of biomass allocated to the grain.”
Dr Malcolm Hawkesford, Head of the Plant Biology and Crop Science Department at Rothamsted Research and lead scientist at Rothamsted for this trial said: “We will perform the proposed controlled experiment in our already established facilities here at Rothamsted Research. This trial will be a significant step forward as we will be able to assess in ‘real environmental conditions’ the potential of these plants to produce more using the same resources and land area as their non-GM counterparts. These field trials are the only way to assess the viability of a solution that can bring economic benefits to farmers, returns to the UK tax payer from the long-term investment in this research, benefits to the UK economy as a whole and the environment in general. Here at Rothamsted we are very happy to provide any further information and explanation on this area of research”.
This article has been republished from materials provided by Rothamsted Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.